Beginning at lower doses allows your body to adapt and minimizes side effects, but may delay peak appetite suppression compared to rapid escalation protocols
We offer structured lifestyle programs, nutrition counseling, behavioral support, exercise guidance, and group classes
eligibility is confirmed during sign-up, but asking upfront saves time
These include diabetes, underactive thyroid, and diseases that affect the nervous system such as Parkinsons or MS
As established earlier, the menopausal transition is associated with a shift toward chronic low-grade inflammation, driven partly by the loss of estrogen's anti-inflammatory signaling and partly by the accumulation of metabolically active visceral fat
New England Journal of Medicine: Retatrutide Phase 2 trial results - The landmark study establishing retatrutide efficacy and safety across multiple dose groups New England Journal of Medicine: STEP 1 semaglutide trial results - The pivotal trial demonstrating semaglutide 2.4 mg weight loss efficacy ClinicalTrials.gov: Retatrutide TRIUMPH program - Current status and details of all ongoing Phase 3 retatrutide trials FDA prescribing information for Wegovy (semaglutide 2.4 mg) - Complete approved labeling including dosing, safety, and clinical data New England Journal of Medicine: SELECT cardiovascular outcomes trial - The trial demonstrating semaglutide 20% reduction in major cardiovascular events These primary sources should be the foundation for any serious evaluation of either compound
